Adulteration meeting set
This article was originally published in The Tan Sheet
FDA schedules a May 1 public meeting to discuss methods for better predicting and preventing economically motivated adulteration of regulated products. The meeting in College Park, Md., will address what industry is doing and could do to prevent EMA. FDA, the U.S. Pharmacopeia and industry stakeholders are revising analytical testing standards to effectively screen for contaminated heparin, diethylene glycol in glycerin and melamine in infant formula - recent instances of EMA (1"The Tan Sheet" Feb. 16, 2009, p. 16)
You may also be interested in...
U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.